Pekin Hardy Strauss, Inc. 89bio, Inc. Transaction History

Pekin Hardy Strauss, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 05, 2024	SELL	$6.66 - $16.03 $42,624 - $102,592	-6,400 Reduced 30.79%	14,385 $160,000
Q3 2023 Nov 07, 2023	SELL	$15.06 - $19.41 $230,418 - $296,973	-15,300 Reduced 42.4%	20,785 $320,000
Q2 2023 Aug 08, 2023	SELL	$14.15 - $22.03 $2.13 Million - $3.32 Million	-150,559 Reduced 80.67%	36,085 $683,000
Q1 2023 May 08, 2023	SELL	$10.48 - $16.94 $86,921 - $140,500	-8,294 Reduced 4.25%	186,644 $2.84 Million
Q4 2022 Feb 13, 2023	SELL	$5.52 - $12.73 $730,836 - $1.69 Million	-132,398 Reduced 40.45%	194,938 $2.48 Million
Q3 2022 Nov 09, 2022	BUY	$3.02 - $7.0 $23,800 - $55,167	7,881 Added 2.47%	327,336 $1.9 Million
Q2 2022 Aug 05, 2022	SELL	$2.09 - $4.02 $86,536 - $166,448	-41,405 Reduced 11.47%	319,455 $1.03 Million
Q1 2022 May 13, 2022	BUY	$3.45 - $14.99 $614,117 - $2.67 Million	178,005 Added 97.35%	360,860 $1.36 Million
Q4 2021 Feb 08, 2022	SELL	$11.15 - $19.66 $23,158 - $40,833	-2,077 Reduced 1.12%	182,855 $2.39 Million
Q3 2021 Nov 12, 2021	SELL	$14.91 - $21.31 $663,867 - $948,827	-44,525 Reduced 19.4%	184,932 $3.62 Million
Q2 2021 Aug 12, 2021	BUY	$17.42 - $28.0 $804,490 - $1.29 Million	46,182 Added 25.2%	229,457 $4.29 Million
Q1 2021 May 13, 2021	BUY	$20.22 - $26.73 $3.71 Million - $4.9 Million	183,275 New	183,275 $4.34 Million

158

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $387M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Pekin Hardy Strauss, Inc., based on Form 13F filings with the SEC.

Stay updated on Pekin Hardy Strauss, Inc. with notifications on news.